Human KIR+CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19
Abstract Previous reports show that Ly49+CD8+ T cells can suppress autoimmunity in mouse models of autoimmune diseases. Here we find a markedly increased frequency of CD8+ T cells expressing inhibitory Killer cell Immunoglobulin like Receptors (KIR), the human equivalent of the Ly49 family, in the blood and inflamed tissues of various autoimmune diseases. Moreover, KIR+CD8+ T cells can efficiently eliminate pathogenic gliadin-specific CD4+ T cells from Celiac disease (CeD) patients’ leukocytes in vitro. Furthermore, we observe elevated levels of KIR+CD8+ T cells, but not CD4+ regulatory T cells, in COVID-19 and influenza-infected patients, and this correlates with disease severity and vasculitis in COVID-19. Expanded KIR+CD8+ T cells from these different diseases display shared phenotypes and similar T cell receptor sequences. These results characterize a regulatory CD8+ T cell subset in humans, broadly active in both autoimmune and infectious diseases, which we hypothesize functions to control self-reactive or otherwise pathogenic T cells.One-Sentence Summary Here we identified KIR+CD8+ T cells as a regulatory CD8+ T cell subset in humans that suppresses self-reactive or otherwise pathogenic CD4+ T cells..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 30. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.12.23.473930 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI033297800 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI033297800 | ||
| 003 | DE-627 | ||
| 005 | 20230429100953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.23.473930 |2 doi | |
| 035 | |a (DE-627)XBI033297800 | ||
| 035 | |a (biorXiv)10.1101/2021.12.23.473930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human KIR+CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Previous reports show that Ly49+CD8+ T cells can suppress autoimmunity in mouse models of autoimmune diseases. Here we find a markedly increased frequency of CD8+ T cells expressing inhibitory Killer cell Immunoglobulin like Receptors (KIR), the human equivalent of the Ly49 family, in the blood and inflamed tissues of various autoimmune diseases. Moreover, KIR+CD8+ T cells can efficiently eliminate pathogenic gliadin-specific CD4+ T cells from Celiac disease (CeD) patients’ leukocytes in vitro. Furthermore, we observe elevated levels of KIR+CD8+ T cells, but not CD4+ regulatory T cells, in COVID-19 and influenza-infected patients, and this correlates with disease severity and vasculitis in COVID-19. Expanded KIR+CD8+ T cells from these different diseases display shared phenotypes and similar T cell receptor sequences. These results characterize a regulatory CD8+ T cell subset in humans, broadly active in both autoimmune and infectious diseases, which we hypothesize functions to control self-reactive or otherwise pathogenic T cells.One-Sentence Summary Here we identified KIR+CD8+ T cells as a regulatory CD8+ T cell subset in humans that suppresses self-reactive or otherwise pathogenic CD4+ T cells. | ||
| 700 | 1 | |a Zaslavsky, Maxim |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Yapeng |e verfasserin |4 aut | |
| 700 | 1 | |a Sikora, Michael J. |e verfasserin |4 aut | |
| 700 | 1 | |a van Unen, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Christophersen, Asbjørn |e verfasserin |4 aut | |
| 700 | 1 | |a Chiou, Shin-Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiefu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xuhuai |e verfasserin |4 aut | |
| 700 | 1 | |a Wilhelmy, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a McSween, Alana M. |e verfasserin |4 aut | |
| 700 | 1 | |a Palanski, Brad A. |e verfasserin |4 aut | |
| 700 | 1 | |a Aditya Mallajosyula, Venkata Vamsee |e verfasserin |4 aut | |
| 700 | 1 | |a Dhondalay, Gopal Krishna R. |e verfasserin |4 aut | |
| 700 | 1 | |a Bhamidipati, Kartik |e verfasserin |4 aut | |
| 700 | 1 | |a Pai, Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Kipp, Lucas B. |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Jeffrey E. |e verfasserin |4 aut | |
| 700 | 1 | |a Hauser, Stephen L. |e verfasserin |4 aut | |
| 700 | 1 | |a Oksenberg, Jorge R. |e verfasserin |4 aut | |
| 700 | 1 | |a Satpathy, Ansuman T. |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, William H. |e verfasserin |4 aut | |
| 700 | 1 | |a Steinmetz, Lars M. |e verfasserin |4 aut | |
| 700 | 1 | |a Khosla, Chaitan |e verfasserin |4 aut | |
| 700 | 1 | |a Utz, Paul J. |e verfasserin |4 aut | |
| 700 | 1 | |a Sollid, Ludvig M. |e verfasserin |4 aut | |
| 700 | 1 | |a Heath, James R. |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Becker, Nielsen Q. |e verfasserin |4 aut | |
| 700 | 1 | |a Nadeau, Kari C. |e verfasserin |4 aut | |
| 700 | 1 | |a Saligrama, Naresha |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Mark M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.23.473930 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||
| 953 | |2 045F |a 570 | ||